Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 5, 2010, Pages 985-990

  Wang, Guo Ping ^a   Guan, Yong Song ^a   Jin, Xin Rong ^a   Jiang, Sha Sha ^a   Lu, Ze Jun ^a   Wu, Yang ^a   Li, Yang ^a   Li, Mei ^a   Luo, Feng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

5 fluorouracil; Carrier erythrocyte; Malignant ascites; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; RBC FU; UNCLASSIFIED DRUG; DRUG CARRIER; SODIUM CHLORIDE; ANTINEOPLASTIC ANTIMETABOLITE; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASCITES; ASCITES FLUID ANALYSIS; BLOOD SAMPLING; BODY WEIGHT; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; ERYTHROCYTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; ANIMAL TISSUE; CELL ENCAPSULATION; DIALYSIS ENCEPHALOPATHY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG TARGETING; FEMALE; MALIGNANT ASCITES; MAXIMUM PLASMA CONCENTRATION; TARGET CELL; ANIMAL; BLOOD; DIALYSIS; DRUG FORMULATION; ERYTHROCYTE TRANSFUSION; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER NEOPLASMS; METABOLISM; OSMOSIS; PERITONEAL NEOPLASMS; PROCEDURES; REVERSED PHASE LIQUID CHROMATOGRAPHY; SECONDARY; TIME; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BODY WEIGHT; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; DIALYSIS; DRUG CARRIERS; DRUG COMPOUNDING; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEMALE; FLUOROURACIL; INJECTIONS, INTRAPERITONEAL; LIPOSOMES; LIVER NEOPLASMS; MICE; OSMOSIS; PERITONEAL NEOPLASMS; TIME FACTORS;

EID: 77951743418     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06155.x     Document Type: Article

References (30)

1. Hellwig U. Red blood cells as carrier systems for drugs. Pharmazie 1990 45 : 824 826.
2. Al-Achi A, Greenwood R. Erythrocytes as oral delivery systems for human insulin. Drug. Dev. Ind. Pharm. 1998 24 : 67 72.
3. Zocchi E, Tonetti M, Polvani C et al. In vivo liver and lung targeting of adriamycin encapsulated in glutaraldehyde-treated murine erythrocytes. Biotechnol. Appl. Biochem. 1988 10 : 555 562.
4. De Flora A, Tonetti M, Zocchi E et al. Engineered erythrocytes as carriers and bioreactors. Year. Immunol. 1993 7 : 168 174.
5. Magnani M, Rossi L, Fraternale A et al. Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Ther. 2002 9 : 749 751.
6. Hamidi M, Tajerzadeh H. Carrier erythrocytes: an overview. Drug Deliv. 2003 10 : 9 20.
7. Luo X, Xu X, Wang XH et al. Study of Erythrocyte as carrier to prolong Morphine's Duration of Action. J. NanJing Univ. (Nat. Sci.) 2003 39 547 553.
8. Wei ZG, Li GX, Huang XC et al. Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats. World J. Gastroenterol. 2008 14 : 2179 2186.
9. Kojiro S, Yano H, Ogasawara S et al. Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. J. Gastroenterol. Hepjatol. 2006 21 : 129 137.
10. Zhang Q, Ni Q, Gan J et al. p14ARF upregulation of p53 and enhanced effects of 5-fluorouracil in pancreatic cancer. Clin. Med. J. (Engl.) 2003 116 : 1150 1155.
11. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin. Surg. Oncol. 1998 14 : 254 261.
12. Mahteme H, Larsson B, Sundin A et al. Uptake of 5-fluorouracil (5-FU) in peritoneal metastases in relation to the route of drug administration and tumour debulking surgery an autoradiographic study in the rat. Eur. J. Cancer 2004 40 : 142 147.
13. Kravtzoff R, Ropars C, Laguerre M et al. Erythrocytes as carriers for l-asparaginase. Methodological and mouse in-vivo studies. J. Pharm. Pharmacol. 1990 42 : 473 476.
14. Ahmed H, Chatterjee BP, Debnath AK. Interaction and in vivo growth inhibition of Ehrlich ascites tumor cells by jacalin. J. Biosci. 1988 13 : 419 424.
15. Li PC, Chen LD, Zheng F, Li Y. Intraperitoneal chemotherapy with hydroxycamptothecin reduces peritoneal carcinomatosis: results of an experimental study. J. Cancer Res. Clin. Oncol. 2008 134 : 37 44.
16. Seike M, Maetani I, Sakai Y. Treatment of malignant ascites in patients with advanced cancer: peritonevenous shunt versus paracentesis. J. Gastroenterol. Hepatol. 2007 22 : 2161 2166.
17. Sugarbaker PH. Adjuvant intraperitoneal chemotherapy: a review. Recent Results Cancer Res. 2007 169 : 83 9.
18. Singhal P, Lele S. Intraperitoneal chemotherapy for ovarian cancer: where are we now? J. Natl. Compr. Canc. Netw. 2006 4 : 941 946.
19. Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat. Res. 1996 82 : 53 63.
20. Yan TD, Black D, Sugarbaker PH et al. A systematic review and mata-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for respectable gastric cancer. Ann. Surg. Oncol. 2007 14 : 2702 2713.
21. Elstein KH, Mole ML, Setzer RW et al. Nucleoside-mediated mitigation of 5-fluorouracil-induced toxicity in synchronized murine erythroleukemic cells. Toxicol. Appl. Pharmacol. 1997 146 : 29 39.
22. Noordhuis P, Holwerda U, Van Der Wilt CL et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancer. Ann. Oncol. 2004 15 : 1025 1032.
23. Lotero LA, Olmos G, Diez JC. Delivery to macrophages and toxic action of etoposide carried in mouse red blood cells. Biochim. Biophys. Acta 2003 1620 : 160 166.
24. Rossi L, Serafini S, Pierigé F et al. Erythrocyte-based drug delivery. Expert. Opin. Drug. Deliv. 2005 2 : 311 322.
25. Schrijvers D. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin. Pharmacokinet. 2003 42 : 779 791.
26. Millán CG, Marinero ML, Castañeda AZ, Lanao JM. Drug, enzyme and peptide delivery using erythrocytes as carriers. J. Control Release 2004 95 : 27 49.
27. Millán CG, Castañeda AZ, López FG et al. Encapsulation and in vitro evaluation of amikacin-loaded erythrocytes. Drug Deliv. 2005 12 : 409 416.
28. Kruse CA, Freehauf CL, Patel KR, Baldeschwieler JD. Mouse erythrocyte carriers osmotically loaded with methotrexate. Biotechnol. Appl. Biochem. 1987 9 : 123 140.
29. Gutiérrez Millán C, Zarzuelo Castañeda A, Sayalero Marinero ML, Lanao JM. Factors associated with the performance of carrier erythrocytes obtained by hypotonic dialysis. Blood. Cells. Mol. Dis. 2004 33 : 132 140.
30. Rossi L, Serafini S, Antonelli A et al. Macrophage depletion induced by clodronate-loaded erythrocytes. J. Drug Target. 2005 13 : 99 111.